Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 4/20 | 0.44 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.43 |
| ▸ | DOT1L | Q8TEK3 | 4/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.41 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13092293 | 1.00 | NT5E (0.44) | NT5EBMPR1BP2RY12DOT1LADORA1 | |
| SCHEMBL25496185 | 0.78 | BMPR1B (0.53) | NT5EBMPR1BP2RY12ADORA1ADORA3 | |
| SCHEMBL26297894 | 0.78 | BMPR1B (0.53) | NT5EBMPR1BP2RY12ADORA1ADORA3 | |
| SCHEMBL29832209 | 0.78 | P2RY12 (0.52) | NT5EBMPR1BP2RY12ADORA1ADORA3 | |
| SCHEMBL19127970 | 0.78 | P2RY12 (0.52) | NT5EBMPR1BP2RY12ADORA1ADORA3 | |
| SCHEMBL18521420 | 0.78 | LMNA (0.60) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL21063207 | 0.78 | LMNA (0.60) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL21625242 | 0.78 | LMNA (0.60) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL314050 | 0.78 | LMNA (0.60) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL23621389 | 0.78 | LMNA (0.60) | ADORA1ADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633168-B2 | Inhibitors of S-adenosyl-L-methionine decarboxylase | GENZYME CORPORATION (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633168-B2 | Inhibitors of S-adenosyl-L-methionine decarboxylase | GENZYME CORPORATION (US) | 2014-01-21 | — | — | US | disclosed |
| US-20100261668-A1 | INHIBITORS OF S-ADENOSYL-L-METHIONINE DECARBOXYLASE | GENZYME CORPORATION | 2010-10-14 | — | — | US | disclosed |
| WO-2008157438-A1 | INHIBITORS OF S-ADENOSYL-L-METHIONINE DECARBOXYLASE | GENZYME CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261668-A1 | INHIBITORS OF S-ADENOSYL-L-METHIONINE DECARBOXYLASE | AMD1, MAT1A, AHCY | NT5E 1191/4885BMPR1B 3911/4885P2RY12 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.